Randomized, controlled trial of telcagepant over four migraine attacks

Andrew P. Ho, Carl G H Dahlöf, Stephen D. Silberstein, Joel R. Saper, Messoud Ashina, James T. Kost, Samar Froman, Heather Leibensperger, Christopher R. Lines, Tony W. Ho

Research output: Contribution to journalArticle

Abstract

Methods: This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, doubleblind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140 mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as ≥3 successes, and lack of consistent efficacy was defined as ≥2 failures, in treatment response. A total of 1677 patients treated ≥1 attack and 1263 treated all four attacks. Results: Based on Attack 1 data, telcagepant 140 mg and 280 mg were significantly (p

Original languageEnglish (US)
Pages (from-to)1443-1457
Number of pages15
JournalCephalalgia
Volume30
Issue number12
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Migraine Disorders
Randomized Controlled Trials
Calcitonin Gene-Related Peptide Receptors
Treatment Failure
Tablets
Placebos
telcagepant
Therapeutics

Keywords

  • Calcitonin gene-related peptide
  • Consistency
  • Migraine
  • Randomized controlled trial
  • Telcagepant

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

Ho, A. P., Dahlöf, C. G. H., Silberstein, S. D., Saper, J. R., Ashina, M., Kost, J. T., ... Ho, T. W. (2010). Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia, 30(12), 1443-1457. https://doi.org/10.1177/0333102410370878

Randomized, controlled trial of telcagepant over four migraine attacks. / Ho, Andrew P.; Dahlöf, Carl G H; Silberstein, Stephen D.; Saper, Joel R.; Ashina, Messoud; Kost, James T.; Froman, Samar; Leibensperger, Heather; Lines, Christopher R.; Ho, Tony W.

In: Cephalalgia, Vol. 30, No. 12, 12.2010, p. 1443-1457.

Research output: Contribution to journalArticle

Ho, AP, Dahlöf, CGH, Silberstein, SD, Saper, JR, Ashina, M, Kost, JT, Froman, S, Leibensperger, H, Lines, CR & Ho, TW 2010, 'Randomized, controlled trial of telcagepant over four migraine attacks', Cephalalgia, vol. 30, no. 12, pp. 1443-1457. https://doi.org/10.1177/0333102410370878
Ho AP, Dahlöf CGH, Silberstein SD, Saper JR, Ashina M, Kost JT et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010 Dec;30(12):1443-1457. https://doi.org/10.1177/0333102410370878
Ho, Andrew P. ; Dahlöf, Carl G H ; Silberstein, Stephen D. ; Saper, Joel R. ; Ashina, Messoud ; Kost, James T. ; Froman, Samar ; Leibensperger, Heather ; Lines, Christopher R. ; Ho, Tony W. / Randomized, controlled trial of telcagepant over four migraine attacks. In: Cephalalgia. 2010 ; Vol. 30, No. 12. pp. 1443-1457.
@article{2b7cdca8c5694dca94faf7afe27cf9d1,
title = "Randomized, controlled trial of telcagepant over four migraine attacks",
abstract = "Methods: This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, doubleblind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140 mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as ≥3 successes, and lack of consistent efficacy was defined as ≥2 failures, in treatment response. A total of 1677 patients treated ≥1 attack and 1263 treated all four attacks. Results: Based on Attack 1 data, telcagepant 140 mg and 280 mg were significantly (p",
keywords = "Calcitonin gene-related peptide, Consistency, Migraine, Randomized controlled trial, Telcagepant",
author = "Ho, {Andrew P.} and Dahl{\"o}f, {Carl G H} and Silberstein, {Stephen D.} and Saper, {Joel R.} and Messoud Ashina and Kost, {James T.} and Samar Froman and Heather Leibensperger and Lines, {Christopher R.} and Ho, {Tony W.}",
year = "2010",
month = "12",
doi = "10.1177/0333102410370878",
language = "English (US)",
volume = "30",
pages = "1443--1457",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Randomized, controlled trial of telcagepant over four migraine attacks

AU - Ho, Andrew P.

AU - Dahlöf, Carl G H

AU - Silberstein, Stephen D.

AU - Saper, Joel R.

AU - Ashina, Messoud

AU - Kost, James T.

AU - Froman, Samar

AU - Leibensperger, Heather

AU - Lines, Christopher R.

AU - Ho, Tony W.

PY - 2010/12

Y1 - 2010/12

N2 - Methods: This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, doubleblind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140 mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as ≥3 successes, and lack of consistent efficacy was defined as ≥2 failures, in treatment response. A total of 1677 patients treated ≥1 attack and 1263 treated all four attacks. Results: Based on Attack 1 data, telcagepant 140 mg and 280 mg were significantly (p

AB - Methods: This study evaluated the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant (tablet formulation) for treatment of a migraine attack and across four attacks. Adults with migraine were randomized, doubleblind, to telcagepant 140 mg, telcagepant 280 mg, or control treatment sequences to treat four moderate-to-severe migraine attacks. Control patients received placebo for three attacks and telcagepant 140 mg for one attack. Efficacy for the first attack (Attack 1) and consistency of efficacy over multiple attacks were assessed. For an individual patient, consistent efficacy was defined as ≥3 successes, and lack of consistent efficacy was defined as ≥2 failures, in treatment response. A total of 1677 patients treated ≥1 attack and 1263 treated all four attacks. Results: Based on Attack 1 data, telcagepant 140 mg and 280 mg were significantly (p

KW - Calcitonin gene-related peptide

KW - Consistency

KW - Migraine

KW - Randomized controlled trial

KW - Telcagepant

UR - http://www.scopus.com/inward/record.url?scp=78650001597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650001597&partnerID=8YFLogxK

U2 - 10.1177/0333102410370878

DO - 10.1177/0333102410370878

M3 - Article

C2 - 20974601

AN - SCOPUS:78650001597

VL - 30

SP - 1443

EP - 1457

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 12

ER -